Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,920
  • Shares Outstanding, K 79,033
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,780 K
  • 60-Month Beta 0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.43
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +88.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.82 +12.80%
on 05/29/19
0.99 -6.57%
on 06/04/19
+0.07 (+8.17%)
since 05/17/19
3-Month
0.76 +20.99%
on 05/13/19
1.10 -15.91%
on 03/20/19
-0.13 (-12.74%)
since 03/18/19
52-Week
0.43 +115.12%
on 08/16/18
1.80 -48.61%
on 10/01/18
+0.25 (+36.03%)
since 06/18/18

Most Recent Stories

More News
Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Settles Claims with Former Chief Executive Officer

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), today announced that it has settled regarding claims made against the Company by its former chief executive officer (the "Former...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Neptune Settles On Claims on Employment Contract By Former Chief Executive Officer

Neptune Wellness Solutions Inc. ("Neptune" or the "Corporation") (NASDAQ: NEPT) (TSX: NEPT), announced that it has settled regarding certain claims made by the Corporation's former chief executive officer...

NEPT.TO : 6.10 (+4.81%)
ACST : 0.93 (+1.65%)
NEPT : 4.53 (+4.86%)
Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

More Than 40% of Patients Have Completed Their 6 Month Treatment Plan

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma Recognized in TSX Venture Exchange's 2019 Venture 50

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

ACST.VN : 1.230 (+1.65%)
ACST : 0.93 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 0.97
1st Resistance Point 0.95
Last Price 0.93
1st Support Level 0.90
2nd Support Level 0.88

See More

52-Week High 1.80
Fibonacci 61.8% 1.28
Fibonacci 50% 1.12
Fibonacci 38.2% 0.95
Last Price 0.93
52-Week Low 0.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar